AU2002337840B2 - Hepatitis C virus vaccine - Google Patents

Hepatitis C virus vaccine Download PDF

Info

Publication number
AU2002337840B2
AU2002337840B2 AU2002337840A AU2002337840A AU2002337840B2 AU 2002337840 B2 AU2002337840 B2 AU 2002337840B2 AU 2002337840 A AU2002337840 A AU 2002337840A AU 2002337840 A AU2002337840 A AU 2002337840A AU 2002337840 B2 AU2002337840 B2 AU 2002337840B2
Authority
AU
Australia
Prior art keywords
seq
base pair
region
nucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002337840A
Other languages
English (en)
Other versions
AU2002337840A1 (en
Inventor
Andrew J Bett
Stefano Colloca
Riccardo Cortese
Emilio A Emini
David C Kaslow
Armin Lahm
Alessandra Luzzago
Alfredo Nicosia
John W Shiver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Merck Sharp and Dohme LLC
Original Assignee
MSD Italia SRL
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD Italia SRL, Merck Sharp and Dohme LLC filed Critical MSD Italia SRL
Publication of AU2002337840A1 publication Critical patent/AU2002337840A1/en
Application granted granted Critical
Publication of AU2002337840B2 publication Critical patent/AU2002337840B2/en
Priority to AU2007231692A priority Critical patent/AU2007231692B8/en
Assigned to ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A, MERCK SHARP & DOHME CORP. reassignment ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A Request to Amend Deed and Register Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A, MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP., ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A, MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP., ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP., ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A
Assigned to MERCK SHARP & DOHME CORP., MSD ITALIA S.R.L. reassignment MERCK SHARP & DOHME CORP. Request for Assignment Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A, MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Assigned to MSD ITALIA S.R.L., MERCK SHARP & DOHME LLC reassignment MSD ITALIA S.R.L. Request for Assignment Assignors: MSD ITALIA S.R.L., MERCK SHARP & DOHME CORP.
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2002337840A 2001-10-11 2002-10-10 Hepatitis C virus vaccine Expired AU2002337840B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007231692A AU2007231692B8 (en) 2001-10-11 2007-10-26 Hepatitis C virus vaccine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32865501P 2001-10-11 2001-10-11
US60/328,655 2001-10-11
US36377402P 2002-03-13 2002-03-13
US60/363,774 2002-03-13
PCT/US2002/032512 WO2003031588A2 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007231692A Division AU2007231692B8 (en) 2001-10-11 2007-10-26 Hepatitis C virus vaccine

Publications (2)

Publication Number Publication Date
AU2002337840A1 AU2002337840A1 (en) 2003-07-03
AU2002337840B2 true AU2002337840B2 (en) 2007-08-09

Family

ID=42828995

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002337840A Expired AU2002337840B2 (en) 2001-10-11 2002-10-10 Hepatitis C virus vaccine

Country Status (9)

Country Link
US (3) US7598362B2 (enExample)
EP (1) EP1436397B1 (enExample)
JP (1) JP4475561B2 (enExample)
CN (1) CN1582337B (enExample)
AT (1) ATE467680T1 (enExample)
AU (1) AU2002337840B2 (enExample)
CA (1) CA2461380C (enExample)
DK (1) DK1436397T3 (enExample)
WO (1) WO2003031588A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1236801A (en) 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
DE60130998T2 (de) 2000-08-17 2008-07-17 Tripep Ab Ribavirin-enthaltende vakzine
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ATE467680T1 (de) * 2001-10-11 2010-05-15 Merck Sharp & Dohme Hepatitis-c-virus-impfstoff
DE60236364D1 (en) * 2001-10-11 2010-06-24 Angeletti P Ist Richerche Bio Hepatitis-c-virus-impfstoff
JP2008518591A (ja) * 2004-11-02 2008-06-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途
EP1846439A2 (en) * 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US7951531B2 (en) * 2005-02-17 2011-05-31 University Of Iowa Research Foundation Flavivirus NS5A proteins for the treatment of HIV
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
CN101213204B (zh) * 2005-06-17 2013-06-19 P.安杰莱蒂分子生物学研究所 丙型肝炎病毒核酸疫苗
CN1887350B (zh) * 2005-06-28 2010-10-06 深圳市源兴生物医药科技有限公司 一种重组疫苗及其用途
CN104984352A (zh) * 2005-11-21 2015-10-21 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
EP2076531B1 (en) 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
US8124108B2 (en) 2007-01-24 2012-02-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2233575A4 (en) * 2007-12-18 2012-12-26 Univ Peking Peoples Hospital ANTI-HCV VACCINE, AND MANUFACTURING METHOD AND USES THEREOF
US20110136896A1 (en) * 2008-08-01 2011-06-09 Tong-Ming Fu Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
WO2010050939A1 (en) * 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
WO2010062814A1 (en) 2008-11-26 2010-06-03 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP2376111A4 (en) 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
BRPI1008018A2 (pt) 2009-02-02 2016-03-15 Okairos Ag ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos
CN102645534B (zh) * 2012-04-26 2015-08-12 杭州市萧山区第一人民医院 基于量子点编码微球芯片检测丙型肝炎病毒的方法
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
EP3244922A4 (en) * 2015-01-15 2018-06-20 Babita Agrawal Methods of inducing an immune response to hepatitis c virus
CN108277230A (zh) * 2018-02-07 2018-07-13 华中科技大学 一种融合dna及其制备的疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0464287A1 (en) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5731172A (en) * 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
JP4051416B2 (ja) 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
EP1009763A4 (en) 1996-06-11 2002-08-07 Merck & Co Inc SYNTHETIC HEPATITIS-C GENES
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
NZ500656A (en) 1997-05-12 2001-11-30 Tno Vector containing a nucleic acid insertion expressing a hybrid polypeptide with a protease inhibitor domain and a receptor binding domain
US6221646B1 (en) * 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
JP2002501737A (ja) 1998-01-30 2002-01-22 ザ・ジェネラル・ホスピタル・コーポレイション Ｃ型肝炎ウイルスの非構造蛋白質による遺伝的免疫感作
CA2328180A1 (en) 1998-04-14 1999-10-21 Merck & Co., Inc. Needleless administration of polynucleotide formulations
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6156588A (en) 1998-06-23 2000-12-05 Vlsi Technology, Inc. Method of forming anti-fuse structure
JP2002523054A (ja) 1998-08-24 2002-07-30 ジェンザイム・コーポレイション ポリマーにより修飾されたアデノウイルスのカチオン性複合体
IL144060A0 (en) 1999-01-14 2002-04-21 Novartis Ag Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
AU1236801A (en) 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
AU2574601A (en) 1999-11-24 2001-06-04 Chiron Corporation Novel hcv non-structural polypeptide
AU5442501A (en) 1999-12-01 2001-07-09 Chiron Corporation Eliciting HCV-specific antibodies
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
ATE467680T1 (de) * 2001-10-11 2010-05-15 Merck Sharp & Dohme Hepatitis-c-virus-impfstoff

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kolykhalov, A.A. et al. (February 2000) J. Virol., Vol. 74(4), pages 2046-2051. *

Also Published As

Publication number Publication date
CN1582337A (zh) 2005-02-16
EP1436397A2 (en) 2004-07-14
WO2003031588A3 (en) 2003-10-30
JP2005505286A (ja) 2005-02-24
EP1436397A4 (en) 2005-02-16
WO2003031588A2 (en) 2003-04-17
US8142794B2 (en) 2012-03-27
CA2461380C (en) 2011-03-22
CA2461380A1 (en) 2003-04-17
US20040247615A1 (en) 2004-12-09
US8530234B2 (en) 2013-09-10
US20100129901A1 (en) 2010-05-27
EP1436397B1 (en) 2010-05-12
US20090233992A1 (en) 2009-09-17
US7598362B2 (en) 2009-10-06
JP4475561B2 (ja) 2010-06-09
ATE467680T1 (de) 2010-05-15
DK1436397T3 (da) 2010-08-09
CN1582337B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
US8142794B2 (en) Hepatitis C virus vaccine
AU2002337840A1 (en) Hepatitis C virus vaccine
Capone et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates
US9056090B2 (en) Hepatitis C virus nucleic acid vaccine
JP2008518591A (ja) 複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途
JP4479973B2 (ja) Ｃ型肝炎ウイルスワクチン
CA2718802C (en) Recombinant nucleic acids comprising regions of ad6
AU2007231692B2 (en) Hepatitis C virus vaccine
CA2629163C (en) Adenoviral vector-based foot-and-mouth disease vaccine
HK1123055B (en) Hepatitis c virus nucleic acid vaccine
HK1155489A (en) Hepatitis c virus vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-PATENTEE NAME FROM MERCK & CO., INC. TO MERCK SHARP & DOHME CORP.

PC Assignment registered

Owner name: MERCK SHARP & DOHME CORP.; MSD ITALIA S.R.L.; MERC

Free format text: FORMER OWNER WAS: MERCK SHARP & DOHME CORP.; ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A

TH Corrigenda

Free format text: IN VOL 28 , NO 35 , PAGE(S) 4784 UNDER THE HEADING ASSIGNMENTS REGISTERED UNDER THE NAME MSD ITALIA S.R.L.; MERCK SHARP & DOHME CORP., APPLICATION NO. 2002337840, UNDER INID (71) CORRECT THE APPLICANT NAME TO MSD ITALIA S.R.L.; MERCK SHARP & DOHME CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired
PC Assignment registered

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER OWNER(S): MSD ITALIA S.R.L.; MERCK SHARP & DOHME CORP.

Owner name: MSD ITALIA S.R.L.

Free format text: FORMER OWNER(S): MSD ITALIA S.R.L.; MERCK SHARP & DOHME CORP.